Nutriband Inc. Scales Manufacturing for AVERSA™ Fentanyl Patch Ahead of FDA Submission

Nutriband Inc. (NASDAQ: NTRB) has achieved significant manufacturing scale-up for its AVERSA™ Fentanyl abuse-deterrent transdermal patch technology through collaboration with Kindeva, positioning the company for imminent FDA submission. This development marks a critical milestone in bringing the innovative product to market, potentially unlocking major revenue opportunities while addressing a pressing public health concern.

The company's proprietary AVERSA™ technology incorporates aversive agents into fentanyl patches to prevent misuse, abuse, diversion, and accidental exposure to the powerful opioid. This technological advancement represents a meaningful step forward in combating the ongoing opioid crisis by providing an additional layer of protection against potential abuse of transdermal fentanyl products.

Nutriband has established a comprehensive global intellectual property protection strategy, securing patents across multiple key markets including the United States, Europe, Asia, and Australia. This robust IP portfolio provides the company with significant competitive advantages and market protection as it moves toward commercialization. The company maintains detailed information about its technology and development progress available at https://www.Nutriband.com.

The manufacturing scale-up achievement enables Nutriband to finalize its development pathway toward FDA approval, with the company maintaining a laser focus on completing regulatory requirements. This progress demonstrates the viability of moving from development phase to commercial production capacity, a crucial step for any pharmaceutical company preparing for market entry.

The potential impact of AVERSA™ technology extends beyond financial opportunities for the company and its shareholders. Successful commercialization could provide healthcare providers and patients with a safer alternative to existing fentanyl patch products, potentially reducing incidents of abuse and accidental exposure. The technology's applicability to any transdermal patch containing drugs with abuse potential suggests broader implications for the pharmaceutical industry's approach to drug safety.

Investors and stakeholders can access the latest developments and updates regarding Nutriband's progress through the company's dedicated newsroom at https://ibn.fm/NTRB. The company's advancement through the regulatory process and manufacturing scale-up positions it at a pivotal moment, with the potential to transform both patient safety in opioid therapy and create substantial value in the pharmaceutical market.